NBP SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

20-F/A

Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]

Jun 16, 2026

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Apr 7, 2026

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Apr 3, 2025

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Apr 30, 2024

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

May 1, 2023

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Apr 29, 2022

News

TYPE

HEADLINE

FILED AT

6-K

NovaBridge Biosciences Appoints Chuck Silberstein as Chief Financial Officer

Oct 28, 2026

6-K

NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development

Oct 26, 2026

6-K

NovaBridge Biosciences Announces Presentation of Phase 1 Clinical Data for Ragistomig at ESMO Congress 2026

Oct 23, 2026

6-K

Visara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic Keratitis

Oct 13, 2026

6-K

NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director

Sep 8, 2026

6-K

NovaBridge Biosciences Announces Voting Results from 2026 Annual General Meeting

Sep 8, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

UPDATED | SHARE RESALE REGISTRATION |

Oct 29, 2025

424B5

REGISTERED OFFERING

Aug 4, 2025

424B5

July ATM | Offering amount: $50,000,000 | Amount sold to date: $0

Jul 11, 2025

424B3

UPDATED

Mar 31, 2022

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 1,036,541 | Share price: $16.42 | Offering amount: $17,017,299.20

Jan 14, 2022

424B3

UPDATED | OFFERING | Shares amount: 1,000,293 | Share price: $27.87 | Offering amount: $27,878,165.90

Nov 26, 2021

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 17, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Sep 11, 2025

F-6EF

Form F-6EF - Registration of American Depository Receipt shares, immediately effective

Aug 1, 2025

F-3

May 2025 SHELF | Float: 153,940,774

May 2, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 30, 2024

S-8

Registration

Jun 17, 2022

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13D/A

HHLR ADVISORS, LTD. (Filed by)

Nov 5, 2026

Silberstein Charles (Reporting)

Nov 2, 2026

Woo Ian Ying (Reporting)

Oct 19, 2026

Dennis Phillip Andrew (Reporting)

Sep 21, 2026

144

Form 144 - Report of proposed sale of securities

Sep 18, 2026

Cao Sean Wuxiong (Reporting)

Sep 11, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

May 16, 2025

LETTER

Form UPLOAD - SEC-generated letter

Aug 14, 2023

CORRESP

Form CORRESP - Correspondence

Aug 7, 2023

LETTER

Form UPLOAD - SEC-generated letter

Jul 27, 2023

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 24, 2021

EFFECT

Form EFFECT - Notice of Effectiveness

Dec 15, 2020

NovaBridge Biosciences NBP · SEC Filings